Notably, a previous transcriptomic study also defined an “inflamed” SCLC subtype (SCLC-I) [15] which was characterized by high expression of genes related to HLAs and experienced greatest benefit from the addition of anti-PD-L1 to chemotherapy [15]. This evidence concerns the gene HLA-S and small cell lung carcinoma.